GT
AMED

Glenmede Trust’s Amedisys AMED Stock Holding History

Glenmede Trust’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed -$1K – 1238
2020
Q3 		$1K Hold
5
– – ﹤0.01% 2316
2020
Q2 		$0 Sell
5
-20,651
-100% -$3.85M ﹤0.01% 2434
2020
Q1 		$3.45M Hold
20,656
– – 0.02% 526
2019
Q4 		$3.45M Sell
20,656
-19,057
-48% -$2.83M 0.02% 526
2019
Q3 		$5.2K Sell
39,713
-14,357
-27% -$1.87M 0.02% 438
2019
Q2 		$6.56K Sell
54,070
-9,884
-15% -$1.17M 0.03% 424
2019
Q1 		$7.88K Sell
63,954
-6,688
-9% -$839K 0.04% 403
2018
Q4 		$8.27K Buy
70,642
+212
+0.3% +$25K 0.04% 365
2018
Q3 		$8.8M Sell
70,430
-1,129
-2% -$125K 0.04% 394
2018
Q2 		$6.12M Buy
71,559
+2,959
+4% +$217K 0.03% 432
2018
Q1 		$3.62M Hold
68,600
– – 0.02% 547
2017
Q4 		$3.62M Buy
68,600
+68,516
+81,567% +$3.61M 0.02% 547
2017
Q3 		$4K Buy
+84
New +$4.44K ﹤0.01% 2386
2013
Q4 		– Sell
-40,400
Closed -$695K – 2277
2013
Q3 		$695K Buy
40,400
+10,410
+35% +$154K 0.01% 741
2013
Q2 		$348K Buy
+29,990
New +$344K ﹤0.01% 893

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Glenmede Trust's AMED Position: Q4 2020 in Review

Glenmede Trust sold out of Amedisys (AMED) in Q4 2020, closing a stake of 5 shares — an estimated $1K sold.

Glenmede Trust first reported a position in AMED in Q2 2013 and held it in 15 quarters. The position peaked at $8.8M in Q3 2018. 396 funds tracked by Wall St. Rank hold AMED as of Q4 2020.

  • Glenmede Trust reported no remaining Amedisys position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 5 Amedisys shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in Amedisys in Q2 2013 and held it in 15 quarters.
  • Glenmede Trust's Amedisys position peaked at $8.8M in Q3 2018.
  • 396 funds tracked by Wall St. Rank held Amedisys as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.